FIGURE 2
Immunohistochemical analysis of Oct2, Oct1, and BOB.1/OBF.1 expression in lymphomas. A, diffuse large B-cell lymphoma (DLBCL) case that is CD20 positive, showing a strong expression for Oct2, Oct1, and BOB.1/OBF.1. B, mantle zone lymphocyte case expressing Oct2, Oct1, and BOB.1/OBF.1. The intensity of signal in the tumor was lower than that observed in residual reactive germinal center lymphocytes (shown using bcl-6 antibody). C, DLBCL CD20 negative case that is CD79a positive, displaying expression for Oct2, Oct1, and BOB.1/OBF.1. D, splenic marginal zone B-cell lymphoma CD20-positive case with expression of Oct2 and its progression to CD20-positive DLBCL with loss of Oct2 expression. E, lymphocyte-predominant Hodgkin’s lymphoma case with lymphocytic and histiocytic cells (L&H) cells showing similar Oct2 (low and high power), Oct1, and BOB.1/OBF.1 expression that found in reactive germinal center. F, T lymphoblastic lymphoma case, CD3 positive, with scattered CD20-reactive lymphocytes. Tumoral cells were Oct2 negative, strongly positive for Oct1, and BOB.1/OBF.1 negative. G, peripheral T-cell lymphoma CD3-positive case, with scattered CD20-reactive lymphocytes, showing expression for Oct2, Oct1, and BOB.1/OBF.1.
